Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease

Summary

This is a Phase 1, open-label, parallel-group study to evaluate rotigotine pharmacokinetics, safety and tolerability following a single intramuscular dose of one of two different formulations of LY03003 in patients with Parkinson's disease.

Timeline

Start

2018-05-15

Primary completion

2018-10-31

Completion

2018-10-31

Drugs

Indications